Piperacillin/Tazobactam Kabi 4 g/0
Sponsors
Medical University Of Vienna, Semmelweis University
Conditions
chronic obstructive pulmonary diseasecritical illnesscystic fibrosispatients with external ventricular drainsuspected or proven infection
Phase 1
Phase 4
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.
Not yet recruitingCTIS2024-518337-29-00
Target: 18Updated: 2024-12-11
A single-centre, partially blind, randomised, parallel-group, two-arms, superiority study to compare the efficacy and safety of extended (3 h) and intermittent infusion (0.5 h) of β-lactams (cefepime, ceftriaxone, meropenem, piperacillin/tazobactam) in critically ill paediatric patients (PEBBLE)
Not yet recruitingCTIS2024-518115-19-02
Target: 110Updated: 2025-09-29